BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia

Experimental Hematology

Volumn 39, Issue 3, 2011, Pages

  Jiang, Nan ^a   Koh, Grace Shimin ^a   Suang Lim, Joshua Yew ^a   Yin Kham, Shirley Kow ^a   Ariffin, Hany ^b   Chew, Fook Tim ^c   Juh Yeoh, Allen Eng ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; CASPASE 3; CASPASE 9; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PREDNISOLONE; PROTEIN BCL 2; SMALL INTERFERING RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; ENZYME ACTIVITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

EID: 79951944939     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.11.009     Document Type: Article

References (26)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
2. Torpy J.M., Lynm C., Glass R.M. JAMA patient page. Acute lymphoblastic leukemia. JAMA 2009, 301:452.
3. Reiter A., Schrappe M., Ludwig W.D., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994, 84:3122-3133.
4. Schrappe M., Reiter A., Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996, 14:2403-2406.
5. Distelhorst C.W. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002, 9:6-19.
6. Bachmann P.S., Gorman R., Papa R.A., et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 2007, 67:4482-4490.
7. Almawi W.Y., Melemedjian O.K., Jaoude M.M. On the link between Bcl-2 family proteins and glucocorticoid-induced apoptosis. J Leukoc Biol 2004, 76:7-14.
8. Tamm I., Richter S., Scholz F., et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004, 5:489-495.
9. Piskunova T.S., Yurova M.N., Ovsyannikov A.I., et al. Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice. Curr Gerontol Geriatr Res 2008, 754190.
10. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004, 83(suppl 1):S121-S123.
11. Schultz K.R., Pullen D.J., Sather H.N., et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007, 109:926-935.
12. Hilden J.M., Dinndorf P.A., Meerbaum S.O., et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006, 108:441-451.
13. Herr I., Gassler N., Friess H., Buchler M.W. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis 2007, 12:271-291.
14. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
15. Chipuk J.E., Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol 2008, 18:157-164.
16. Wang Z., Malone M.H., He H., McColl K.S., Distelhorst C.W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003, 278:23861-23867.
17. Zhang L., Insel P.A. The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells. J Biol Chem 2004, 279:20858-20865.
18. Iglesias-Serret D., de Frias M., Santidrian A.F., et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007, 21:281-287.
19. Rambal A.A., Panaguiton Z.L., Kramer L., Grant S., Harada H. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia 2009, 23:1744-1754.
20. Bouillet P., Zhang L.C., Huang D.C., et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome 2001, 12:163-168.
21. Puthalakath H., Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002, 9:505-512.
22. Dijkers P.F., Medema R.H., Lammers J.W., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000, 10:1201-1204.
23. Planey S.L., Abrams M.T., Robertson N.M., Litwack G. Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Res 2003, 63:172-178.
24. Zhao Y., Tan J., Zhuang L., Jiang X., Liu E.T., Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 2005, 102:16090-16095.
25. Lu J., Quearry B., Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006, 580:3539-3544.
26. Yamamura Y., Lee W.L., Inoue K., Ida H., Ito Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 2006, 281:5267-5276.